• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

慢性粒细胞白血病治疗期间频繁更换酪氨酸激酶抑制剂，主要原因是不耐受，且不影响生存率：一项魁北克前瞻性注册研究

Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study.

作者信息

Busque Lambert, Beaudet Marc-Étienne, Harnois Michaël, Moussa Hanane, Szuber Natasha, Mollica Luigina, Delage Robert, Olney Harold, Laneuville Pierre, Cournoyer Ghislain, Chamakhi Inès, Lalancette Marc, Talbot Danielle, Ethier Vincent, Desjardins Pierre, Assouline Sarit

机构信息

Institut universitaire d'hémato-oncologie et de thérapie cellulaire (IHOT), Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada.

Université de Montréal, Montréal, QC, Canada.

出版信息

Blood Cancer J. 2025 Mar 11;15(1):35. doi: 10.1038/s41408-025-01242-8.

DOI:10.1038/s41408-025-01242-8
PMID:40069191
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11897363/
Abstract

[Image: see text]

摘要

[图像：见正文]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a09b/11897363/e3de0da8ebd8/41408_2025_1242_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a09b/11897363/430cb06887cb/41408_2025_1242_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a09b/11897363/e3de0da8ebd8/41408_2025_1242_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a09b/11897363/430cb06887cb/41408_2025_1242_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a09b/11897363/e3de0da8ebd8/41408_2025_1242_Fig2_HTML.jpg

相似文献

1
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study.慢性粒细胞白血病治疗期间频繁更换酪氨酸激酶抑制剂，主要原因是不耐受，且不影响生存率：一项魁北克前瞻性注册研究
Blood Cancer J. 2025 Mar 11;15(1):35. doi: 10.1038/s41408-025-01242-8.
2
Comment on: "Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study" by Busque et al.对Busque等人所著的《慢性粒细胞白血病治疗期间频繁更换酪氨酸激酶抑制剂，主要由不耐受驱动，且不影响生存率：一项魁北克前瞻性登记研究》的评论
Blood Cancer J. 2025 Apr 19;15(1):70. doi: 10.1038/s41408-025-01288-8.
3
Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry.慢性髓性白血病（CML）一线酪氨酸激酶抑制剂（TKI）治疗20年的真实世界证据：来自ACHO的RENEHOC注册研究的见解
Clin Lymphoma Myeloma Leuk. 2025 May;25(5):e290-e301. doi: 10.1016/j.clml.2024.12.015. Epub 2024 Dec 28.
4
Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.在常规临床实践中使用 ponatinib 治疗费城染色体阳性白血病患者的临床结果-来自比利时注册处的数据。
Ann Hematol. 2021 Jul;100(7):1723-1732. doi: 10.1007/s00277-021-04507-x. Epub 2021 May 4.
5
Chronic Myeloid Leukemia: A Review.慢性髓性白血病：综述
JAMA. 2025 May 13;333(18):1618-1629. doi: 10.1001/jama.2025.0220.
6
Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.伊马替尼治疗后序贯二代酪氨酸激酶抑制剂在儿童慢性髓性白血病中的应用：来自日本儿科白血病/淋巴瘤研究组的报告。
Pediatr Blood Cancer. 2018 Dec;65(12):e27368. doi: 10.1002/pbc.27368. Epub 2018 Aug 7.
7
Developing therapeutic approaches for chronic myeloid leukemia: a review.开发治疗慢性髓细胞白血病的方法：综述。
Mol Cell Biochem. 2023 May;478(5):1013-1029. doi: 10.1007/s11010-022-04576-0. Epub 2022 Oct 10.
8
The New ELN Recommendations for Treating CML.欧洲白血病网络（ELN）治疗慢性粒细胞白血病的新建议
J Clin Med. 2020 Nov 16;9(11):3671. doi: 10.3390/jcm9113671.
9
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.慢性髓性白血病：诊断、治疗和监测的 2025 年更新。
Am J Hematol. 2024 Nov;99(11):2191-2212. doi: 10.1002/ajh.27443. Epub 2024 Aug 2.
10
Current status and novel strategy of CML.慢性粒细胞白血病的现状与新策略
Int J Hematol. 2021 May;113(5):624-631. doi: 10.1007/s12185-021-03127-5. Epub 2021 Mar 29.

引用本文的文献

1
Potential therapeutic targets in chronic myeloid leukemia.慢性髓性白血病中的潜在治疗靶点。
Med Oncol. 2025 Jul 17;42(8):344. doi: 10.1007/s12032-025-02895-y.
2
Comment on: "Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study" by Busque et al.对Busque等人所著的《慢性粒细胞白血病治疗期间频繁更换酪氨酸激酶抑制剂，主要由不耐受驱动，且不影响生存率：一项魁北克前瞻性登记研究》的评论
Blood Cancer J. 2025 Apr 19;15(1):70. doi: 10.1038/s41408-025-01288-8.

本文引用的文献

1
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.阿西替尼治疗新诊断的慢性髓性白血病。
N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31.
2
Real-world Management of CML: Outcomes and Treatment Patterns.真实世界中 CML 的管理：结局和治疗模式。
Curr Hematol Malig Rep. 2023 Oct;18(5):167-175. doi: 10.1007/s11899-023-00703-w. Epub 2023 Jul 3.
3
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
阿西替尼对比博舒替尼治疗至少两种酪氨酸激酶抑制剂治疗后的慢性期慢性髓性白血病：ASCEMBL 的长期随访。
Leukemia. 2023 Mar;37(3):617-626. doi: 10.1038/s41375-023-01829-9. Epub 2023 Jan 30.
4
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.两种酪氨酸激酶抑制剂治疗失败后的慢性期慢性髓性白血病患者中，asciminib 与其他治疗药物的匹配调整间接比较。
J Cancer Res Clin Oncol. 2023 Aug;149(9):6247-6262. doi: 10.1007/s00432-022-04562-5. Epub 2023 Jan 28.
5
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.低剂量达沙替尼 50mg/天与标准剂量达沙替尼 100mg/天作为慢性髓性白血病慢性期一线治疗的比较：倾向评分分析。
Am J Hematol. 2022 Nov;97(11):1413-1418. doi: 10.1002/ajh.26689. Epub 2022 Aug 27.
6
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option.酪氨酸激酶抑制剂治疗慢性髓性白血病的长期安全性评估——当无治疗缓解不是选择时应注意什么。
Blood Rev. 2022 Nov;56:100968. doi: 10.1016/j.blre.2022.100968. Epub 2022 May 6.
7
Treatment-Free Remission: the New Goal in CML Therapy.无治疗缓解：CML 治疗的新目标。
Curr Hematol Malig Rep. 2021 Oct;16(5):433-439. doi: 10.1007/s11899-021-00653-1. Epub 2021 Oct 7.
8
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.一项 3 期、开放标签、随机研究，评估了 STAMP 抑制剂 ASCiminib 与博舒替尼（一种二代 TKI）在 2 种或更多种 TKI 治疗后 CML 患者中的疗效。
Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984.
9
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.基于治疗药物监测的达沙替尼剂量优化可降低慢性髓性白血病患者胸腔积液发生率。
Br J Haematol. 2021 Jul;194(2):393-402. doi: 10.1111/bjh.17654. Epub 2021 Jun 30.
10
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.慢性髓性白血病患者的预期寿命接近普通人群。
J Clin Oncol. 2016 Aug 20;34(24):2851-7. doi: 10.1200/JCO.2015.66.2866. Epub 2016 Jun 20.